Skip to Main Content

Nearly a dozen advocacy groups have complained to Congress that a recent Department of Commerce draft report that offered ways to modernize technology transfer and innovation would limit the ability of the federal government to curb “excessive” prescription drug prices.

The 135-page report, which was issued last December by the department’s National Institute of Standards and Technology, broadly addresses innovation and proposes various suggestions for maximizing returns on taxpayer investment in R&D.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!